Neeraj Agarwal
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal is Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, USA. He directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. Agarwal is a panel member for the National Comprehensive Cancer Network (NCCN) Guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the U.S. Food and Drug Administration (FDA) and leads early therapeutics in the Southwest Oncology Group (SWOG) GU cancers committee.
Disclosures: Consultancy: Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis Oncology, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, MEI Pharma, Merck, Nektar Therapeutics, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Research funding: Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis Oncology, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Medivation, Merck, Nektar Therapeutics, NewLink Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.
View content featuring Agarwal:
This content has been developed independently by Medthority who previously received educational funding from Pfizer in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
of interest
are looking at
saved
next event